BRPI0922302B8 - extrudados com substâncias ativas aciculares, seu uso, e medicamentos - Google Patents

extrudados com substâncias ativas aciculares, seu uso, e medicamentos

Info

Publication number
BRPI0922302B8
BRPI0922302B8 BRPI0922302A BRPI0922302A BRPI0922302B8 BR PI0922302 B8 BRPI0922302 B8 BR PI0922302B8 BR PI0922302 A BRPI0922302 A BR PI0922302A BR PI0922302 A BRPI0922302 A BR PI0922302A BR PI0922302 B8 BRPI0922302 B8 BR PI0922302B8
Authority
BR
Brazil
Prior art keywords
medicines
extruded
active substances
acicular
acicular active
Prior art date
Application number
BRPI0922302A
Other languages
English (en)
Inventor
Hamann Hans-Jürgen
Kleinebudde Peter
Witzleb Rieke
Kanikanti Venkata-Rangarao
Original Assignee
Bayer Animal Health Gmbh
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41785839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922302(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh, Bayer Ip Gmbh filed Critical Bayer Animal Health Gmbh
Publication of BRPI0922302A2 publication Critical patent/BRPI0922302A2/pt
Publication of BRPI0922302B1 publication Critical patent/BRPI0922302B1/pt
Publication of BRPI0922302B8 publication Critical patent/BRPI0922302B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/606Salicylic acid; Derivatives thereof having amino groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

extrudados com substâncias ativas aciculares. a invenção refere-se a extrudados contendo pelo menos uma substância farmaceuticamente ativa na forma da agulhas, na qual a razão do tamanho de partícula da substância farmaceuticamente ativa em forma de agulha em relação ao diâmetro do cordão é de pelo menos 1:15, e ao uso desses extrudados para a produção de medicamentos.
BRPI0922302A 2008-12-05 2009-11-24 extrudados com substâncias ativas aciculares, seu uso, e medicamentos BRPI0922302B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008060472.0 2008-12-05
DE102008060472 2008-12-05
PCT/EP2009/008341 WO2010063387A1 (de) 2008-12-05 2009-11-24 Extrudate mit nadelförmigen wirkstoffen

Publications (3)

Publication Number Publication Date
BRPI0922302A2 BRPI0922302A2 (pt) 2016-01-05
BRPI0922302B1 BRPI0922302B1 (pt) 2020-09-15
BRPI0922302B8 true BRPI0922302B8 (pt) 2021-05-25

Family

ID=41785839

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922302A BRPI0922302B8 (pt) 2008-12-05 2009-11-24 extrudados com substâncias ativas aciculares, seu uso, e medicamentos

Country Status (27)

Country Link
US (1) US20120034273A1 (pt)
EP (1) EP2373287B1 (pt)
JP (2) JP5860284B2 (pt)
KR (1) KR20110096145A (pt)
CN (1) CN102238940B (pt)
AR (1) AR075106A1 (pt)
AU (1) AU2009321822B2 (pt)
BR (1) BRPI0922302B8 (pt)
CA (1) CA2745456A1 (pt)
CL (1) CL2011001207A1 (pt)
CO (1) CO6440550A2 (pt)
CR (1) CR20110285A (pt)
DO (1) DOP2011000160A (pt)
EC (1) ECSP11011080A (pt)
ES (1) ES2685472T3 (pt)
IL (1) IL212846A0 (pt)
MX (1) MX2011005572A (pt)
NI (1) NI201100103A (pt)
NZ (1) NZ593217A (pt)
PE (1) PE20120182A1 (pt)
RU (1) RU2549450C2 (pt)
SV (1) SV2011003919A (pt)
TW (1) TWI522114B (pt)
UA (1) UA105648C2 (pt)
UY (1) UY32287A (pt)
WO (1) WO2010063387A1 (pt)
ZA (1) ZA201104145B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231017B1 (hu) * 2012-05-08 2019-11-28 LAVET Gyógyszeripari Kft. Praziquantel tartalmú ízfedett formulációk
EP2968569A4 (en) * 2013-03-15 2016-11-02 Argenta Mfg Ltd COUGAR FORMULATION
IN2013MU03583A (pt) * 2013-11-14 2015-07-31 Cipla Ltd
CA3049952A1 (en) 2017-07-26 2019-01-31 Tgx Soft Chew, Llc Starch-free soft chew for veterinary applications
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4402752B2 (ja) * 1997-05-19 2010-01-20 大日本住友製薬株式会社 免疫増強製剤
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
ATE431738T1 (de) * 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20060153908A1 (en) * 2002-06-27 2006-07-13 Brian Strong Spherical pellet formulations
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
SI1566173T1 (sl) * 2004-02-20 2006-12-31 Mattern Udo Farmacevtska zmes za oralno aplikacijo in postopek njene priprave
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
JPWO2006090640A1 (ja) * 2005-02-23 2008-07-24 太陽化学株式会社 アミノ酸含有錠剤組成物および錠剤の製造方法
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
WO2008063301A2 (en) * 2006-10-11 2008-05-29 Alpharma, Inc. Pharmaceutical compositions
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
CN101590020B (zh) * 2008-05-30 2012-02-08 上海新菲尔生物制药工程技术有限公司 一种对氨基水杨酸钠结肠定位给药系统

Also Published As

Publication number Publication date
ES2685472T3 (es) 2018-10-09
CN102238940A (zh) 2011-11-09
UY32287A (es) 2010-06-30
SV2011003919A (es) 2011-08-28
CN102238940B (zh) 2014-07-30
NI201100103A (es) 2012-04-16
ECSP11011080A (es) 2011-06-30
UA105648C2 (uk) 2014-06-10
DOP2011000160A (es) 2011-06-30
AU2009321822A1 (en) 2011-06-30
NZ593217A (en) 2013-05-31
CR20110285A (es) 2011-09-27
TWI522114B (zh) 2016-02-21
KR20110096145A (ko) 2011-08-29
HK1163547A1 (en) 2012-09-14
US20120034273A1 (en) 2012-02-09
CL2011001207A1 (es) 2011-10-28
EP2373287B1 (de) 2018-05-30
CA2745456A1 (en) 2010-06-10
AR075106A1 (es) 2011-03-09
ZA201104145B (en) 2012-09-26
PE20120182A1 (es) 2012-02-24
RU2011127248A (ru) 2013-01-10
CO6440550A2 (es) 2012-05-15
JP2015134812A (ja) 2015-07-27
MX2011005572A (es) 2011-06-16
JP5860284B2 (ja) 2016-02-16
AU2009321822B2 (en) 2015-04-16
BRPI0922302A2 (pt) 2016-01-05
BRPI0922302B1 (pt) 2020-09-15
WO2010063387A1 (de) 2010-06-10
EP2373287A1 (de) 2011-10-12
JP2012510956A (ja) 2012-05-17
IL212846A0 (en) 2011-07-31
TW201031422A (en) 2010-09-01
RU2549450C2 (ru) 2015-04-27

Similar Documents

Publication Publication Date Title
BRPI1008023B8 (pt) Forma de dosagem sólida
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
BRPI0922302B8 (pt) extrudados com substâncias ativas aciculares, seu uso, e medicamentos
BR112012007206A2 (pt) dispositivo de distribuição de fármacos
CL2008001821A1 (es) Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
BRPI0800212A (pt) sistema de envio de lente
MX2011013539A (es) Tabletas de farmaco solidas para dispositivos implantables para administrar farmacos.
AR096115A1 (es) Modificaciones cristalinas del elobixibat
ECSP13012618A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
BRPI0812432B8 (pt) extrusados, seu uso, e medicamento
BR112012023912A2 (pt) produto de artigos de confeitaria contendo componentes ativos e/ou reativos e métodos de produção do mesmo
DOP2013000224A (es) Uso de 2,3-dihidroimidazo[1,2-c] quinazolinas sustituidas.
BR112015020000A2 (pt) fibra kraft quimicamente modificada e métodos de fabricação da mesma
CR20150455A (es) Imidazopiridazinas sustituidas
BRPI0909330A2 (pt) Método para produzir uma mistura de bacteriófagos, medicamento, mistura de fago e o uso da mesma na terapia de estafilococos resistentes a antibiótico
ES2582927T3 (es) Adhesivo para la fabricación de laminados de productos de celulosa y procedimientos de fabricación de laminados de productos de celulosa
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
ES2720955T3 (es) Método para la fabricación de productos de construcción basados en yeso
CL2013002777A1 (es) Proceso para la preparacion de particulas de pigmentos autoaglutinantes, en que dicho aglutinante comprende una carboximetilcelulosa; suspension de particulas de pigmentos autoaglutinantes; y su uso.
PE20160048A1 (es) Composiciones antibioticas de ceftolozano
BR112012023431A2 (pt) dispositivo de distribuição de fármacos
BR112014020033A8 (pt) Materiais compósitos para uso em dispositivos de alta voltagem
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
BR112015011180A2 (pt) sistema de absorção de fluido unitário para produtos absorventes e seus métodos de fabricação

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B25A Requested transfer of rights approved

Owner name: BAYER ANIMAL HEALTH GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: ELANCO ANIMAL HEALTH GMBH (DE)

B25G Requested change of headquarter approved

Owner name: ELANCO ANIMAL HEALTH GMBH (DE)